PMID: 7523340Sep 30, 1994Paper

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications

International Journal of Radiation Oncology, Biology, Physics
V S KavadiA Pollack

Abstract

Serum prostate-specific antigen (PSA) levels following definitive radiation for prostate cancer are increasingly recognized as the most sensitive means to monitor disease status. However, beyond general agreement that patients fare poorly when posttreatment PSA levels fail to normalize, many questions relative to postirradiation PSA remain unanswered. This study evaluates the potential prognostic value of postirradiation PSA in a large cohort of patients followed with serial PSA determinations. We analyzed disease outcome in 427 patients with clinical stages T1 (122 men), T2 (147 men), T3 (152 men), and T4 (six men) prostate cancer receiving definitive external radiation as sole therapy and followed for times ranging from 9-73 months (median 30 months) with a total of 2260 posttreatment PSA values. Excluding three patients who died due to intercurrent illness without a posttreatment PSA, postirradiation PSA fell in 416 of 424 men (98%). Prostate-specific antigen levels continued to fall for up to 12 months but there was no evidence of significant declines beyond that. The time to nadir PSA was: 3 months, 60 patients; 6 months, 68 patients, 9 months 148 patients; 12 months, 144 patients. Time to nadir was not a significant deter...Continue Reading

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·G K Zagars
Apr 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J FijuthF Reboul
Sep 1, 1990·International Journal of Radiation Oncology, Biology, Physics·A G MeekL Wielopolski
Nov 1, 1989·International Journal of Radiation Oncology, Biology, Physics·C Landmann, R Hunig
Feb 1, 1994·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·G K Zagars, A Pollack

❮ Previous
Next ❯

Citations

Jul 8, 1999·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·S WachterR Pötter
May 15, 1995·International Journal of Radiation Oncology, Biology, Physics·G K ZagarsA C von Eschenbach
Aug 30, 1995·International Journal of Radiation Oncology, Biology, Physics·G K ZagarsA C von Eschenbach
Feb 1, 1996·International Journal of Radiation Oncology, Biology, Physics·A PollackI I Rosen
Apr 27, 2005·International Journal of Radiation Oncology, Biology, Physics·Kent WallnerWayne Butler
Aug 1, 1996·Urology·J K Cohen
Mar 1, 1997·Urology·P R CarrollM Roach
Oct 23, 1997·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·G K Zagars, A Pollack
Oct 23, 1997·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·E M HorwitzA A Martinez
Aug 3, 2001·International Journal of Radiation Oncology, Biology, Physics·J M TaylorH M Sandler
Sep 24, 2002·International Journal of Radiation Oncology, Biology, Physics·Torunn I YockJohn J Coen
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Zvi SymonHoward M Sandler
Oct 1, 1996·International Journal of Radiation Oncology, Biology, Physics·E M HorwitzA A Martinez
Oct 1, 1996·International Journal of Radiation Oncology, Biology, Physics·R E Peschel
Jan 15, 1997·International Journal of Radiation Oncology, Biology, Physics·S H StokesW Kan
Jul 15, 1997·International Journal of Radiation Oncology, Biology, Physics·C I SartorH M Sandler
Jun 1, 1997·International Journal of Radiation Oncology, Biology, Physics·J P LattanziG E Hanks
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyZ Fuks
Dec 31, 2002·Urologic Oncology·Tony Y EngTerrence S Herman
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R AlmuftiB You
Aug 24, 1999·The Journal of Urology·J W DavisP F Schellhammer
Apr 18, 2002·International Journal of Radiation Oncology, Biology, Physics·Joseph M KaminskiGerald E Hanks
Apr 29, 1998·Seminars in Radiation Oncology·A Pollack, G K Zagars
Jun 17, 1998·The Journal of Urology·G F GreeneA C Von Eschenbach
May 24, 2001·Hematology/oncology Clinics of North America·K Wallner
May 1, 1997·The Urologic Clinics of North America·J A ConnollyP R Carroll
May 9, 2003·The Urologic Clinics of North America·Alan PollackAlexandra L Hanlon
May 20, 2015·The Journal of Urology·Mohamed JallohPeter R Carroll
May 17, 2007·Journal of Clinical Ultrasound : JCU·Robert E KrischPeter H Arger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.